Compound takes

Afamelanotide is approved for EPP photoprotection, not for cosmetic tanning, libido, vitiligo, melanotan-market, or general sun-tolerance use.

Desmopressin is an approved medicine with serious sodium and fluid-balance risks, not a general hydration, endurance, sleep, wellness, or testing-workaround product.

Oxytocin is an approved obstetric medicine, not a bonding hormone, libido enhancer, social-confidence tool, autism treatment shortcut, wellness spray, or gray-market peptide.

PT-141 is best understood through the approved Vyleesi HSDD evidence, not generic libido, male performance, tanning, melanotan, or gray-market peptide claims.

Semaglutide has FDA-approved product labels for specific uses; compounded, salt-form, and online-market claims need separate quality and dosing-risk review.

Setmelanotide is FDA-approved for specific MC4-pathway obesity conditions, not as a general weight-loss, wellness, tanning, libido, or peptide-market fat-loss product.

Tesamorelin has controlled human data for reducing visceral abdominal fat in HIV lipodystrophy. People also discuss it for body composition, cutting, and anti-aging, but those uses sit inside the GH/IGF-1 risk profile and much weaker non-label evidence.

Tirzepatide has FDA-approved product labels for specific uses; compounded, clinic, gray-market, or off-label marketing claims need separate support.

Vasopressin is a critical-care pressor medicine, not a cognition, bonding, hydration, sleep, anti-aging, social, performance, or wellness peptide.

Cagrilintide is a real clinical-development molecule, not just a peptide-market keyword. Its evidence belongs to investigational amylin-analogue trials, while non-approved products carry separate regulatory and quality risks.

CagriSema has stronger human evidence than most peptide-market combinations, but it remains investigational rather than approved, interchangeable with component products, or self-directed.

Melanotan-1 usually points back to afamelanotide, but Scenesse evidence is narrow to EPP and separate from unregulated melanotan products.

Retatrutide has substantial clinical-development evidence, but trial results, sponsor updates, approval status, and online RETA product claims remain separate questions.

Sermorelin is a historical GHRH reference with narrow pediatric GHD and diagnostic evidence, not a basis for adult anti-aging, body-composition, performance, or wellness claims.

The strongest SS-31 data are for FDA-approved Forzinity in Barth syndrome. Primary mitochondrial myopathy, AMD, cardiovascular, fatigue, performance, and longevity claims need their own direct support.

ARA-290 / cibinetide has narrow disease-specific evidence. The useful human data come from investigational small-fiber-neuropathy research, not generic repair, pain-cure, anti-aging, or consumer-use claims.

Many human trials of contested quality; approved in some countries, not the US.

CJC-1295 DAC has DAC-specific investigational context: healthy-adult endocrine pharmacology, terminated registry context, regulatory review, and product-quality risk, not body-composition, anti-aging, recovery, or stack claims.

GHK-Cu is strongest for route- and formulation-specific topical dermatology claims. Topical wound and skin sources do not imply injectable or systemic benefits.

Real human endocrine data and a Japanese diagnostic approval; performance and physique claims remain unproven.

Gonadorelin has historical and specialist human reproductive-endocrinology evidence, current cattle-only veterinary labels, and public fertility or hormone-optimization claims that need to stay separated.

Kisspeptin-10 is an investigational reproductive-endocrinology peptide. The evidence supports controlled human GnRH and gonadotropin-axis research, not fertility optimization, libido, testosterone, puberty self-management, or public-use claims.

Thymosin alpha-1 has to be judged by clinical setting: chronic hepatitis B has the clearest historical positive signal, sepsis has a modern non-confirmatory phase 3 result, COVID and vaccine-response evidence is mixed or selected, and clinic wellness claims need direct evidence.

Real but unrealized drug research; CIRS-style use is unproven and needs monitoring.

Human trials discontinued over safety events; not a viable use candidate.

Failed obesity drug with persistent fat-loss marketing; human trial evidence does not show benefit.

BPC-157 has limited human evidence. The most useful sources are an oral trial registry, small human reports, review context, and FDA compounding concerns; the recovery protocol culture is much louder than the human data.

Bioregulator with lineage-only evidence.

Cartalax is reasonable to discuss as a cartilage-themed peptide, but it should not be presented as a cartilage-regeneration, osteoarthritis, osteoporosis, recovery, or longevity therapy.

Bioregulator with lineage-only evidence.

The official RIMSO-50 label supports a narrow intravesical interstitial-cystitis context; transdermal, mixing, access, or at-home use claims need their own product and route evidence.

DSIP has older sleep-study history, but that history does not automatically support personal-use, opioid-withdrawal, narcolepsy, or recovery claims.

Epitalon has mechanism and review sources, but clinical longevity and sleep benefits have not been shown in outcome trials.

Animal myostatin data only; no human physique evidence.

Animal myostatin data only; no human physique evidence.

Read KPV and GHK-Cu separately first, then treat the blend as a product-quality and claim-specific problem until direct combination studies exist.

Documented acute GH release in small human studies; marketed outcomes are unproven.

Treat injectable glutathione claims as route-specific evidence and product-quality review. Oncology-adjunct, cosmetic, Parkinson's, wellness, and compounding claims are separate questions, not one interchangeable evidence story.

Potent but non-selective secretagogue; human data are endocrine-only.

Ipamorelin is an investigational GH secretagogue with compounding-policy concerns. The current evidence is limited to healthy-volunteer PK/PD, postoperative-ileus registry context, and FDA 503A review rather than approved GHD, anti-aging, body-composition, recovery, or stack claims.

KPV is mostly a preclinical topic. The literature explains why gut, skin, wound, and antimicrobial claims exist, but it does not provide a human treatment protocol.

The levocarnitine label supports a mitochondrial transport description and specific medical contexts; fat-loss, performance, injectable wellness, and self-directed use claims need their own evidence.

Bioregulator with lineage-only evidence.

LL-37 is best read as a narrow investigational chronic-wound topic. The available sources do not support antimicrobial wellness claims, cancer-treatment claims, immune-boosting language, or public-use directions.

Melanotan-2 is not an FDA-approved tanning product. Regulators tie it to unregulated tanning-market promotion, and approved melanocortin drug labels do not transfer to it.

Use the approved label to separate emergency methemoglobinemia treatment, IV-only product context, and major interaction warnings from nootropic, mitochondrial, anti-aging, access, or at-home claims.

MOTS-c remains research-first. Human sources currently show biomarker or association findings, while efficacy, longevity, and use claims still need direct intervention results.

NAD+ is included because peptide clinics and vendors discuss it beside mitochondrial peptides, but it is not a peptide and does not inherit credibility from peptide profiles or precursor research.

Bioregulator with lineage-only evidence.

Bioregulator with lineage-only evidence.

Pinealon is not a sleep treatment plan or sleep-loss workaround. EDR mechanism sources need to stay separate from REM, occasional-use, and combined-use claims.

Limited Russian clinical literature; elsewhere unproven.

Semax can be described as a CNS-oriented peptide with limited route-specific human evidence, but subcutaneous superiority remains a clinic and forum claim rather than a demonstrated human route advantage.

Early preclinical research only.

Legacy Russian immune preparation with old, low-quality human literature.

Russian-registered thymic peptide; limited old human literature.

Thymosin beta-4 has its own evidence. Eye-drop, wound, IV, and registry sources do not prove consumer recovery benefit, and TB-500/Ac-LKKTETQ fragment sources are not interchangeable full-length thymosin beta-4 evidence.

Bioregulator with lineage-only evidence.

Adamax is a Semax analogue people discuss for focus and neurorecovery, but its dose, duration, safety, and product-identity questions should stay separate from parent-Semax evidence.

BAC water is the diluent, not the active compound. It matters for terminology, sterility, preservative exposure, compatibility, storage, and product quality; it cannot validate the peptide product itself.

CJC-1295 no DAC is an identity and non-interchangeability topic. FDA separates non-DAC and DAC CJC-1295 as different active moieties, and DAC human pharmacology and registry evidence does not carry over to no-DAC CJC-1295 or Modified GRF products.

Popular secretagogue stack with no direct human outcome data; component quality and ratio are unverified.

Vendor blend category; evaluate components, not the bundle.

Community staple with no meaningful human evidence; often confused with the trialed derivative AOD-9604.

Potent research analog with no human evidence; same cautions as IGF-1 LR3.

Full review is pending; use the evidence table before drawing conclusions.

Variable vendor blend; verify composition before interpreting any claim.

No human evidence.

Vendor-invented analog; no published evidence.

Vendor-invented analog; no published evidence.

Animal-only evidence.

Clinic staple combination without direct human outcome data.

TB-500 is not interchangeable with full-length thymosin beta-4. Current evidence separates Ac-LKKTETQ identity and animal or in-vitro work from adjacent full-length thymosin beta-4 human trial records.

The blend is popular because both component names carry repair stories, but human evidence is indirect, TB-500 identity is often blurred with full-length thymosin beta-4, and gray-market quality claims are not clinical validation.